BioSpace News Archive

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it has entered into an exclusive option and research collaboration agreement with Prime Medicine, Inc. (“Prime”), a company founded to deliver on the promise of Prime Editing.

Select Medical Holdings Corporation, will release the financial results for its first quarter ended March 31, 2022 on Thursday, May 5, 2022 after the market closes.

ImmuneID today announced strategic partnerships with two world-class healthcare research organizations.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology portfolio, including the findings on lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody being developed for the treatment of early Alzheimer’s disease (AD) at the American Academy.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery.

Biognosys announced today the details of its presence at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held April 8-13, 2022.

Gnubiotics Sciences SA today announced a poster presentation on the use of Glycopeptides to promote anti-cancer immune response against solid tumors at the American Association for Cancer Research (AACR) Annual Meeting 2022, scheduled for April 8-13, 2022 in New Orleans, Louisiana (USA).

f5 Therapeutics Incorporated today announced that they have been selected as a ‘Cool Company’ for the second year in a row.

Materna Medical announced the completion of the activation of the fifteenth U.S. clinical study site participating in the pivotal EASE trial.

Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m.